Много упреков обычно получают эндокринологи от некоторых участников наших разговоров ,что .дескать ,ничего не делаем для изучения ,профилактики ,включения защитных сил и выключения нападающих сил ,надо полагать .
. Вот коротенькая выдержка по вторичной профилактике СД1 - одна из многочисленных работ,о которых мы много раз говорили .
Anti-CD3 Monoclonal Antibody Slows New-Onset Type 1 Diabetes
Laurie Barclay, MD
May 30, 2002 — When it comes to controlling type 1 diabetes mellitus, there's bad news and good news in the May 30 issue of the New England Journal of Medicine. The bad news is that the long-awaited results of the first part of the Diabetes Prevention Trial (DPT-1) are disappointing: injected insulin does not delay or prevent type 1 diabetes for those at risk, although trials with oral insulin are still ongoing.
But the good news offers hope of a new treatment frontier: attacking the immune origins of the disease to halt progression rather than just control symptoms. Humanized anti-CD3 monoclonal antibody given over 14 days within 6 weeks of diagnosis maintained or improved insulin production for 1 year in 9 of 12 diabetics.
"The most important implication of this research is that we can intervene in type 1 diabetes after onset and still have an impact," senior author Jeffrey Bluestone, director of the UCSF Diabetes Center, tells WebMD. "This opens up the door to a whole host of other approaches, not just this drug."
Bluestone has filed a patent application for this monoclonal antibody and has a commercial agreement regarding its use with Centocor and Johnson & Johnson Pharmaceuticals. "By targeting specific T cells mediating autoimmunity, this drug can modulate the disease by preserving islet cell function," he says. "This brings us one step closer to treating the disease before symptom onset or even before clinical diagnosis, if we can identify those at risk."
|